Back to search results

PCOM2: Improving HPV Vaccination Rates in Adolescents

This study, called PCOM2, is testing ways to help doctors talk to parents about the Human Papillomavirus (HPV) vaccine for their children. Poor communication can lead to low vaccination rates, leaving many young people at risk for HPV-related cancers. Researchers are comparing two methods: "Physician Communication 2 Virtual (PCOM2-virtual)" and "Physician Communication Standard (PCOM-standard)". Both methods train doctors to use a "presumptive technique" (assuming the parent will vaccinate) followed by "motivational interviewing" (helping parents address concerns). PCOM2-virtual is a new online version, while PCOM-standard is in-person. The goal is to see if the virtual training is just as effective at increasing HPV vaccination rates in 11-12 year olds. The study plans to enroll 120 participants.

Study design
This is an interventional study comparing two different communication training methods for healthcare providers. It aims to enroll 120 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Adolescent vaccination initiation status will be assessed among all active 11 to 12-year-old patients at each practice during the last 12 months of the 24-month intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05336240

PCOM2 - The Physician Communication Intervention, Version 2.0

Recruiting
NAAges 9–17InterventionalHealth services
University of Colorado, Denver
~120 participants
Updated 2024-08-26 on ClinicalTrials.gov
What's tested:Physician Communication 2 Virtual (PCOM2-virtual)Physician Communication Standard (PCOM-standard)

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
HPV vaccination initiation status in 11-12 year olds
Measured over Adolescent vaccination initiation status will be assessed among all "active" (seen in the last 12 months) 11 to 12-year-old patients at each practice during the last 12 months of the 24 month intervention period

Conditions

HPV Infection
Preventive Health Services

Explore related trials

Human Papillomavirus Infection

Where it's being run

2 sites across 2 states
Colorado1
Kansas1

Study leadership

  • Sean O'Leary, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver

Who to contact

Christine Spina, MSPH
[email protected]
303.724.0906
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Parents: Have an adolescent between the ages of 9-17 years old and receiving adolescent care at an enrolled clinic
Providers: All providers at participating study practices will be eligible to participate.

Exclusion

Parents: Does not have an adolescent between the ages of 9-17 years old and is not receiving adolescent care at an enrolled clinic
Providers: Providers who are not at participating study practices

What this trial measures

  • HPV vaccination initiation status in 11-12 year oldsAdolescent vaccination initiation status will be assessed among all "active" (seen in the last 12 months) 11 to 12-year-old patients at each practice during the last 12 months of the 24 month intervention period

    The primary outcome to be assessed in the trial is HPV vaccine series initiation among 11-12-year-olds as 11-12 year-olds are the preferred target population for HPV vaccination and the PCOM intervention had its strongest effect on series initiation rather than completion.